52w high/low | ₹7.61 / ₹3.61 |
P/E ratio | 0 |
Dividend | 0 |
ROE | 0.04 |
ROCE | -2.54 |
Face value | 10 |
Book value | ₹-5.14Cr |
Market capital | ₹9.23Cr |
What is shareholding pattern? Who are shareholders?
What is a cash flow statement?
What is a balance sheet?
What is a profit and loss statement?
What are dividends?
What are bonuses?
Mesco Pharmaceuticals started commercial operations in Jun. '91 by venturing into seed-marketing of bulk drugs and formulations with the objective of later establishing facilities for manufacture of bulk drugs and formulations. It set up a formulation plant to manufacture injectables, syrups, ointments and tablets/capsules. The company in technical partnership with Merz, Germany, introduced two drugs -- Hepa Merz and Viru Merz -- for hepatitis (liver disorder) and herpes respectively. It is now developing drugs for cardio-vascular diseases and Parkinson's disease. Apart from Merz, Mesco has technical agreements with two Chinese companies -- Guilin Pharmaceutical Factory and China Science & Resources Technology Trading Corporation. The company has expanded its marketing network to the CIS, Italy, Germany and Africa. It is setting up a multi-purpose bulk drug plant with sterile technology to manufacture the latest bulk drugs, in technical collaboration with Chementechno, Austria.